Merck Sues Cobalt Over ANDA For Generic Fosamax

Law360, New York (June 30, 2005, 12:00 AM EDT) -- Drug maker Merck & Co. has sued Canada’s Cobalt Pharmaceuticals over its plans to make a generic version of its best-selling osteoporosis treatment Fosamax.

The lawsuit, filed in the U.S. District Court for the District of Delaware, accuses Cobalt of infringing eight patents that are set to expire between 2012 and 2018.

Merck filed the complaint after receiving notice that Cobalt had filed an abbreviated new drug application (ANDA) with the U.S. Food and Drug Administration for 35, 40 and 70 mg alendronate sodium tablets, the...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.